Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Intralymphatic Immunotherapy : Update and Unmet Needs

Senti, Gabriela ; Freiburghaus, Andreas U. ; Larenas-Linnemann, Désirée ; Hoffmann, Hans Jürgen ; Patterson, Amber M. ; Klimek, Ludger ; Di Bona, Danilo ; Pfaar, Oliver ; Ahlbeck, Lars and Akdis, Mübeccel , et al. (2019) In International Archives of Allergy and Immunology 178(2). p.141-149
Abstract

Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1... (More)

Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Allergen-specific immunotherapy, Allergy, Clinical trials, Intralymphatic immunotherapy
in
International Archives of Allergy and Immunology
volume
178
issue
2
pages
141 - 149
publisher
Karger
external identifiers
  • scopus:85056460849
  • pmid:30391954
ISSN
1018-2438
DOI
10.1159/000493647
language
English
LU publication?
no
id
9c2f3c68-e627-405f-bf91-c442e777d040
date added to LUP
2018-11-28 14:39:01
date last changed
2024-04-15 17:42:48
@article{9c2f3c68-e627-405f-bf91-c442e777d040,
  abstract     = {{<p>Allergen-specific immunotherapy (AIT) is the only allergy treatment that confers long-term symptom amelioration for patients suffering from allergy. The most frequently used allergen application route is subcutaneous injection (SCIT), commonly taken as the gold standard, followed by sublingual (SLIT) or oral (OIT) application of allergen preparations. This is an up-to-date review of the clinical evidence for a novel route of allergen application, i.e., directly into lymph nodes - intralymphatic immunotherapy (ILIT). The major advantages of ILIT over the current AIT approaches are its short duration and the low allergen doses administered. The whole treatment consists of merely 3 ultrasound-guided injections into inguinal lymph nodes 1 month apart. While the number of patients included in randomised controlled trials is still limited, the clinical results for ILIT are encouraging, but more clinical trials are needed, as well as more preclinical work for optimising formulations.</p>}},
  author       = {{Senti, Gabriela and Freiburghaus, Andreas U. and Larenas-Linnemann, Désirée and Hoffmann, Hans Jürgen and Patterson, Amber M. and Klimek, Ludger and Di Bona, Danilo and Pfaar, Oliver and Ahlbeck, Lars and Akdis, Mübeccel and Weinfeld, Dan and Contreras-Verduzco, Francisco A. and Pedroza-Melendez, Alvaro and Skaarup, Søren H. and Lee, Sang Min and Cardell, Lars Olaf and Schmid, Johannes M. and Westin, Ulla and Dollner, Ralph and Kündig, Thomas M.}},
  issn         = {{1018-2438}},
  keywords     = {{Allergen-specific immunotherapy; Allergy; Clinical trials; Intralymphatic immunotherapy}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{141--149}},
  publisher    = {{Karger}},
  series       = {{International Archives of Allergy and Immunology}},
  title        = {{Intralymphatic Immunotherapy : Update and Unmet Needs}},
  url          = {{http://dx.doi.org/10.1159/000493647}},
  doi          = {{10.1159/000493647}},
  volume       = {{178}},
  year         = {{2019}},
}